Navigation Links
Burrill & Company Invests in Taiwan Liposome Company
Date:7/7/2009

SAN FRANCISCO and TAIPEI, Taiwan, July 7 /PRNewswire/ -- US Venture Capital firm Burrill & Company has invested in Taiwan Liposome Company (http://www.tlcbio.com), a Taiwan based company with operations in Taipei and South San Francisco. Taiwan Liposome Company ("TLC"), is a specialty pharmaceutical company with a proprietary drug delivery technology based on a lipid formulation platform.

TLC is developing and commercializing a portfolio of "super-generics" with advantageous delivery or formulation characteristics. Some of these products include TLC's lead product, ProFlow (used to treat peripheral arterial disease and diabetic neuropathy), which is currently undergoing product development and registration in Asian markets. The company's ovarian and breast cancer treatment, Lipo-Dox, is already marketed in Taiwan.

"We believe that TLC's core advantage of applying proprietary drug delivery technology to extend product lifecycles with performance improvements enables TLC to develop and commercialize new formulations of products with significant market potential," said Burrill & Company General Partner, Dr. Ann Hanham. "We are eager to see the wide roll-out of products derived from this technology to treat diseases that would otherwise be difficult to target, such as certain types of cancer," added Marietta Wu, Director, Burrill & Company.

"It is exciting and stimulating for TLC to have Burrill & Company as a new addition to our current investors. We will benefit greatly from Burrill's extensive international experience and expertise, elevating TLC to becoming a global biotechnology company," said TLC Chairman, Dr. Keelung Hong. "Having Burrill & Company on board is a strong and accredited proof of TLC's capabilities and potential, the successful closing of this round of financing will enable TLC to focus on bringing better medical solutions for patients in need," added George Yeh, President of TLC.

Burrill & Company was joined in this Series A round of financing by YFY Biotech Management Company, TaiAn Technologies Eminent VC, Boston Life Science Venture Corp., and other earlier investors. The proceeds will serve to advance the development of its lead product and prepare the company for an IPO in Taiwan.

About Taiwan Liposome Company

Incorporated in 1997, Taiwan Liposome Company is a biopharmaceutical company engaging in research, development and commercialization of proprietary drug delivery system for improving the treatment of cancer, ophthalmic conditions, and infectious diseases. TLC founded and led by renowned scientist, Dr. Keelung Hong, who has over 30 years of research and development experience in liposomes with over 100 publications. TLC also has a team of researchers, management, production experts, and advisors who are building the company into an organization recognized for its excellence in targeted delivery and rapid advancement of products through the drug development process in South San Francisco, California and Taipei.

About Burrill & Company

Founded in 1994, Burrill & Company is a San Francisco-based global leader in life sciences with activities in Venture Capital, Private Equity, Merchant Banking and Media. The Burrill family of venture capital funds has over $950 million under management and its merchant banking business is one of the industry leaders in life sciences transactions. Burrill is also the creator, sponsor and facilitator of over a dozen leading industry conferences worldwide and publisher of a range of bio-intelligence reports including the monthly Burrill Report, which tracks the progress of the global biotechnology industry and annual "State of the Industry" report the latest of which is Biotech 2009-Life Sciences: Navigating the Sea Change, the 23rd annual report on the industry. The 470-plus page book contains analysis and perspectives on the performance of the industry in 2008 and projections for 2009 and beyond. For more information, visit

http://www.burrillandco.com


'/>"/>
SOURCE Burrill & Company
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Shawn Cross Joins Burrill Merchant Banking
2. Larta Institute Partners With Burrill & Company to Present the 14th Annual Life Sciences Venture Forum
3. Burrill Merchant Banking Advises Faes Farma on Bilastine Licensing Agreement
4. Burrill Merchant Banking Advises NPS on Phase III Licensing Agreement
5. Burrill & Company Announces Promotions
6. The 3rd Annual Burrill Personalized Medicine Meeting November 12-13, 2007 in San Francisco
7. iCardiac Selected by Top 10 Pharmaceutical Company
8. NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd. and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million; Funds Will Support Expansion Activities in the United State
9. Bion Announces Approval of New U.S. Patent that Broadens Protection for the Companys Livestock Waste Environmental Treatment Processes
10. CEL-SCI Files Patent Application to Support Companys Treatment for More Virulent Strain of H1N1 Swine and Other Influenza Viruses
11. Solon Manufacturing Company Acquires PurFybr Brands; Adds Influenza Virus Diagnostic Swabs to Product Line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... Nov. 30, 2016 Biotest Pharmaceuticals Corporation (BPC), ... to announce the addition of its newest plasma collection ... Nebraska . The 15,200 square foot state-of-the-art facility ... 2016 and brings the total number of BPC,s plasma ... Carlisle , BPC,s Chief Executive Officer said "We are ...
(Date:11/30/2016)... DIEGO and BEIJING , ... a leading commercial provider of genomic services and solutions ... announced today that it has completed a USD $75 ... Merchants Bank Co., Ltd.,s CMB International Capital Management ( ... Innovation Investment Management Co., Ltd. ("SDIC Innovation") and Shanghai ...
(Date:11/30/2016)... ... November 30, 2016 , ... SSCI, the established leader in ... implications of the latest FDA guidance on pharmaceutical cocrystals as drug substance . ... MA. , The event follows the successful November 15th event that took ...
(Date:11/30/2016)... ... November 30, 2016 , ... With growth rates averaging more than ... years and look forward to continuing their expansion in their new office space. The ... has been traditionally favoured by the creative industries, so Random42 Scientific Communication will fit ...
Breaking Biology Technology:
(Date:6/3/2016)... Das DOTM (Department ... hat ein 44 Millionen $-Projekt ... einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an Decatur ... Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale Anbieter ... aber Decatur wurde als konformste und innovativste ...
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
Breaking Biology News(10 mins):